Literature DB >> 22735789

The utilization of palliative care in gynecologic oncology patients near the end of life.

Janelle Fauci1, Kellie Schneider, Christy Walters, Jonathan Boone, Jenny Whitworth, Ellie Killian, J Michael Straughn.   

Abstract

BACKGROUND: Palliative and supportive care services provide excellent care to patients near the end of life. It is estimated that enrollment in such services can reduce end-of-life costs; however, there is limited data available regarding the impact of palliative services in end-of-life care in gynecologic oncology patients. We examined the use of palliative services in gynecologic oncology patients during the last six months of life.
METHODS: After IRB approval, a retrospective chart review of patients with a diagnosis of a gynecologic malignancy who died between June 2007 and June 2010 was performed. Abstracted data included demographics, admission and procedural history, use of anti-cancer therapy, and palliative care utilization during the last six months of life.
RESULTS: 268 patients were identified. Most patients were white (76.9%) and had ovarian cancer (56.7%). During the last six months of life, 155 (57.8%) patients underwent anti-cancer therapy with chemotherapy, 19 (7.1%) patients were treated with radiation therapy, and 17 patients (6.3%) underwent treatment with both. 218 patients (81.3%) had at least one admission during this time (range 0-14). The most common reason for admission was gastrointestinal complaints (37.1%), followed by admissions for procedures (18.3%). The median time between the last admission and death was 32 days. 157 patients (58.6%) underwent at least one procedure during the last six months of life (range 0-11). The most common procedure performed was paracentesis (22.6%). 198 (73.9%) patients died at home or in a palliative care unit. 189 (70.5%) patients were referred to hospice or palliative care. 3.2% underwent a procedure or treatment with chemotherapy or radiation after hospice enrollment. The median time between hospice enrollment and death was 22 days. 55% of patients were enrolled in hospice less than 30 days before death. Of the 79 patients not referred to hospice, only 16.5% had documentation of refusing hospice services.
CONCLUSIONS: During the last six months of life, the majority of gynecologic oncology patients receive anticancer therapy and many have repeated hospital admissions. While the majority of patients are referred for palliative care, it appears that most patients spend less than 30 days on hospice. Earlier referral could decrease the number of hospital admissions and procedures while providing invaluable support during this end of life transition.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22735789     DOI: 10.1016/j.ygyno.2012.06.025

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  Functional trajectories in the year before hospice.

Authors:  Hans F Stabenau; Laura J Morrison; Evelyne A Gahbauer; Linda Leo-Summers; Heather G Allore; Thomas M Gill
Journal:  Ann Fam Med       Date:  2015 Jan-Feb       Impact factor: 5.166

2.  Racial and ethnic disparities in palliative care utilization among gynecological cancer patients.

Authors:  Jessica Y Islam; April Deveaux; Rebecca A Previs; Tomi Akinyemiju
Journal:  Gynecol Oncol       Date:  2020-12-02       Impact factor: 5.482

Review 3.  Contributions of the Japanese Gynecologic Oncology Group (JGOG) in Improving the Quality of Life in Women With Gynecological Malignancies.

Authors:  Masayuki Futagami; Yoshihito Yokoyama; Muneaki Shimada; Shinya Sato; Etsuko Miyagi; Akiko Tozawa-Ono; Nao Suzuki; Masaki Fujimura; Yoichi Aoki; Satoru Sagae; Toru Sugiyama
Journal:  Curr Oncol Rep       Date:  2017-04       Impact factor: 5.075

4.  End-of-life care of women with gynecologic malignancies: a pilot study.

Authors:  Nicole S Nevadunsky; Lori Spoozak; Sharon Gordon; Enid Rivera; Kimala Harris; Gary L Goldberg
Journal:  Int J Gynecol Cancer       Date:  2013-03       Impact factor: 3.437

5.  Designing an Educational Website to Improve Quality of Supportive Oncology Care for Women with Ovarian Cancer: An Expert Usability Review and Analysis.

Authors:  Molly A McClellan; Raghav Pavan Karumur; Rachel Isaksson Vogel; Sue V Petzel; Julie Cragg; Daniel Chan; Julie A Jacko; François Sainfort; Melissa A Geller
Journal:  Int J Hum Comput Interact       Date:  2016-01-11       Impact factor: 3.353

6.  Missed opportunities: Patterns of medical care and hospice utilization among ovarian cancer patients.

Authors:  Alaina J Brown; Charlotte C Sun; Lauren S Prescott; Jolyn S Taylor; Lois M Ramondetta; Diane C Bodurka
Journal:  Gynecol Oncol       Date:  2014-09-02       Impact factor: 5.482

7.  Assessment of palliative care training in gynecologic oncology: a gynecologic oncology fellow research network study.

Authors:  Ramez N Eskander; Kathryn Osann; Elizabeth Dickson; Laura L Holman; J Alejandro Rauh-Hain; Lori Spoozak; Eijean Wu; Lauren Krill; Amanda Nickles Fader; Krishnansu S Tewari
Journal:  Gynecol Oncol       Date:  2014-06-02       Impact factor: 5.482

8.  Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer.

Authors:  Hiroko Machida; Aida Moeini; Marcia A Ciccone; Sayedamin Mostofizadeh; Tsuyoshi Takiuchi; Laurie L Brunette; Lynda D Roman; Koji Matsuo
Journal:  Am J Clin Oncol       Date:  2018-09       Impact factor: 2.339

9.  The earlier the better: the role of palliative care consultation on aggressive end of life care, hospice utilization, and advance care planning documentation among gynecologic oncology patients.

Authors:  Mali K Schneiter; Mohana B Karlekar; Marta A Crispens; Lauren S Prescott; Alaina J Brown
Journal:  Support Care Cancer       Date:  2018-09-12       Impact factor: 3.603

10.  Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.

Authors:  Ellinor Östensson; Maria Fröberg; Amy Leval; Ann-Cathrin Hellström; Magnus Bäcklund; Niklas Zethraeus; Sonia Andersson
Journal:  PLoS One       Date:  2015-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.